Konsultacje w zakresie onkologii i radioterapii
Dr hab. med. Krzysztof Roszkowski prof. nadzw.
specjalista onkologii radioterapii
Ordynator Oddziału Klinicznego Radioterapii
Kierownik Zakładu Radioterapii
Centrum Onkologii im. prof. Łukaszczyka w Bydgoszczy
ul. I. Romanowskiej 2, 85-796 Bydgoszcz
Profesor nadzw. Uniwersytet Mikołaja Kopernika,
Katedra i Klinika Onkologii, Radioterapii i Ginekologii Onkologicznej
Redaktor Naczelny czasopisma
“Journal of Hematology and Oncology Research”
https://openaccesspub.org/journal/jhor
American Society of Clinical Oncology (ASCO)
American Society for Therapeutic Radiology and Oncology (ASTRO)
Konsultacje w czwartki: od godz. 16.30
Publikacje naukowe:
1Rhone P, Ruszkowska-Ciastek B, Bielawski K, Brkic A, Zarychta E, Góralczyk B, Roszkowski K, Rość D. Comprehensive analysis of haemostatic profile depending on clinicopathological determinants in breast cancer patients. Biosci Rep. 2018 Feb 23. pii: BSR20171657.
2Harat M, Małkowski B, Wiatrowska I, Makarewicz R, Roszkowski K. Relationship between Glioblastoma Dose Volume Parameters Measured by Dual Time Point Fluoroethylthyrosine-PET and Clinical Outcomes. Front Neurol. 2018 Jan 22;8:756.
3Bajek A, Olkowska J, Walentowicz-Sadłecka M, Sadłecki P, Grabiec M, Porowińska D, Drewa T, Roszkowski K. Human Adipose-Derived and Amniotic Fluid-Derived Stem Cells: A Preliminary In Vitro Comparing Myogenic Differentiation Capability. Med Sci Monit 2017; 23, DOI: 10.12659/MSM.905826
4Bajek A, Porowinska D, Roszkowski K. Influence of extracellular matrix on the proliferation and adhesion properties of stem cells derived from different sources. European Journal of Biological Research. 2017, 7(3): 165-171.
5Roszkowski K, Furtak J, Zurawski B, Szylberg T, Lewandowska MA. Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions. Int. J. Mol. Sci. 2016, 17, 1876.
6Brozyna AA, Jozwicki W, Roszkowski K, Filipiak J, Slominski AT. Melanin content in melanoma metastases affects the outcome of radiotherapy. Oncotarget 2016; Feb 20: 1-10.
7Bialas M, Pankowska V, Bondos J, Roszkowski K. Comparative assessment of hypofractionated radiation therapy and standard treatment in patients with prostate cancer. Journal of Clinical Oncology 2016; 34: suppl; e16616.
8Pankowska V, Malkowski B, Malkowski B, Roszkowski K. Predictive value of 11C-Acetate PET/CT in metastatic renal cell carcinoma. Initial results. Journal of Clinical Oncology 2016; 34: suppl; e16088.
9Czubak K, Lewandowska MA, Klonowska K, Roszkowski K, Kowalewski J, Figlerowicz M, Kozlowski P. High copy number variation of cancer-related microRNA genes and frequent amplification of DICER1 and DROSHA in lung cancer. Oncotarget 2015 Sep 15; 6(27):23399-416.
10Roszkowski K, Filipiak J, Wisniewska M, Mucha-Malecka A, Basta P. Potential survival markers in cancer patients undergoing chemotherapy. Clin Exp Med. 2015 Aug;15(3):381-7.
11Pawel Basta, Anna Bak, Krzysztof Roszkowski. Cancer treatment in pregnant women. Contemp Oncol (Pozn) 2015; 19 (5): 354–360.
12Brozyna AA, Jozwicki W, Roszkowski K, Slominski AT. Pigmentation in melanoma metastases affects response to radiotherapy in melanoma patients. JOURNAL OF INVESTIGATIVE DERMATOLOGY 2015; 135 (8): S6-S6.
13Stasienko E, Wisniewska M, Kamecki K, Skręt-Magierlo J, Opławski M, Brozyna A, Malenczyk M, Koper K, Roszkowski K. Histology of endometriosis-associated ovarian carcinomas. Current Gynecologic Oncology 07/2015; 13(2):85-92.
14Szymanski P, Blaszczyk P, Bak A, Sitarz R, Indrak K, Roszkowski K. Influence of strong antioxidant supplementation on the level of oxidative DNA damage/oxidative stress in head and neck cancer patients undergoing radiotherapy. J Clin Oncol 2015; 33: suppl; e17004.
15Koper K, Wicherek L, Kojs Z, Chamier-Cieminska A, Roszkowski K. The analysis of sHLA-G antigen blood serum concentration levels during radical therapy for gynecological malignancies. J Clin Oncol 2015; 33: suppl; e22192.
16Roszkowski K. Oxidative DNA Damage – the possible use of biomarkers as additional prognostic factors in oncology. Frontiers Bioscence-Landmark Edition, 2014; 19: 808-817.
17Roszkowski K, Zurawski B, Jozwicki W, Basta P, Lewandowska MA. Impact of specific KRAS mutation in exon 2 on clinical outcome of chemotherapy- and radiotherapy-treated colorectal adenocarcinoma patients. Mol Diagn Ther. 2014 Oct;18(5):559-66.
18Dziaman T, Banaszkiewicz Z, Roszkowski K, Gackowski D, Wisniewska E, Rozalski R, Foksinski M, Siomek A, Speina E, Winczura A, Marszalek A, Tudek B, Olinski R. 8-Oxo-7,8-dihydroguanine and uric acid as efficient predictors of survival in colon cancer patients. Int J Cancer. 2014 Jan 15;134(2):376-83.
19Lewandowska MA, Furtak J, Szylberg T, Roszkowski K. An Analysis of the Prognostic Value of IDH1 (Isocitrate Dehydrogenase 1) Mutation in Polish Glioma Patients. Mol Diagn Ther. 2014; 18(1): 45-53.
20Roszkowski K, Blaszczyk P, Mucha-Malecka A, Bak A, Karczewska G, Makowska P. Oxidative DNA damage repair products as molecular markers of cancer. Journal of Clinical Oncology 2014; 32(15): suppl; e13525.
21Roszkowski K, Zurawski B, Basta P, Jozwicki W, Lewandowska MA. Mutation analysis in colorectal adenocarcinoma specimens to targeted treatment. Journal of Clinical Oncology 2014; 32(15): suppl; e14639.
22Karczewska G, Blaszczyk P, Roszkowski K. The outcomes of the treatment of centrally located brain gliomas diagnosed with stereotactic biopsy. Journal of Clinical Oncology 2014; 32(15): suppl; e13009
23Roszkowski K, Basta P. Tangential radiotherapy and electron beam intraoperative radiotherapy in pregnancy associated breast cancer. Archives of Perinatal Medicine 2013; 19(4): 187-190.
24Bak A, Roszkowski K. Oxidative stress in pregnant women. Archives of Perinatal Medicine 2013; 19(3): 150-155.
25Roszkowski K. Analysis of oxidative DNA damage / oxidative stress markers in patients with ovarian cancer. American Journal of Clinical and Experimental Medicine 2013; 1 (2): 40-3.
26Roszkowski K, Olinski R. Urinary 8-oxoguanine as a predictor of survival in patients undergoing radiotherapy. Journal of Clinical Oncology 2013; 31(15): suppl; e22197.
27Roszkowski K. Influence of Beta vulgaris supplementation on the level of oxidative DNA damage/oxidative stress in head and neck cancer patients undergoing radiotherapy. J Nucl Med Radiation Therapy 2012; 3-4: 1-5.
28Malecki K, Glinski B, Mucha-Malecka A, Roszkowski K, Hetnal M. Predictive and prognostic value of p53, Ki-67 and EGFR in patients with advanced oral cavity and oropharyngeal cancer treated with induction chemotherapy. Przegl Lek 2012; 69(1): 5-8.
29Roszkowski K, Olinski R. Urinary 8-Oxoguanine as a Predictor of Survival in Patients Undergoing Radiotherapy. Cancer Epidemiol Biomarkers Prev 2012; 21: 629-34.
30Wicherek L, Jozwicki W, Windorbska W, Roszkowsk K, Lukaszewska E, Wisniewski M, Brozyna AA, Basta P, Skret-Magierlo J, Kope Kr, Rokita W, Dutsch-Wicherek M. Analysis of Treg Cell Population Alterations in the Peripheral Blood of Patients Treated Surgically for Ovarian Cancer – A Preliminary Report. Am J Reprod Immunol 2011; 66(5): 444-50.
31Roszkowski K, Jozwicki W, Blaszczyk P, Mucha-Malecka A, Siomek A. Oxidative damage DNA: 8-oxoGua and 8-oxodG as molecular markers of cancer. Med Sci Monit 2011; 17(6): 329-33.
32Lewandowski R, Roszkowski K, Lewandowska MA. Personalized medicine in oncology: vision or realistic concept? Contemporary Oncology 2011; 15(1): 1-6.
33Błaszczyk P, Mucha-Małecka A, Błaszczyk E, Roszkowski K. Dynamic contrast-enhanced magnetic resonance in the evaluation of stage prostate cancer. Oncology and Radiotherapy 2011; 2(16): 44-51.
34Malecki K, Glinski B, Mucha-Malecka A, Rys J, Kruczak A, Roszkowski K, Urbanska-Gasiorowska M, Hetnal M. Prognostic and predictive significance of p53, EGFr, Ki67 in larynx preservation treatment. Rep Pract Oncol Radiother 2010; 15: 87-92
35Dziaman T, Huzarski T, Gackowski D, Rozalski R Siomek A, Szpila A, Guz J, Lubinski J, Wasowicz W, Roszkowski K, Olinski R. Selenium supplementation reduced oxidative DNA damage in adnexectomized BRCA1 mutations carriers. Cancer Epidemiol Biomarkers Prev 2009: 18(11): 2923-8.
36Blaszczyk P, Roszkowski K, Blaszczyk E, Kowalewski J. Assessment of factors connected with radiotherapy influencing the cosmetic effect in breast conserving therapy. Contemporary Oncology 2009; 13 (3): 129-33.
37Roszkowski K, Blaszczyk P. Oxidative DNA damage as a potential marker for radiotherapy. Contemporary Oncology 2009; 13 (3): 125-8.
38Roszkowski K, Mucha-Malecka A. Tissue and molecular response to the ionizing radiation. Oncology and Radiotherapy 2009; 3(9): 27-32.
39Mucha-Malecka A, Glinski B, Malecki K, Roszkowski K, Urbanska-Gasiorowska M. Pleomorphic xanthoastrocytoma clinical features, treatment and prognosis. Rewiev of the literature. Oncology and Radiotherapy 2009; 3(9): 41-47.
40Roszkowski K, Blaszczyk P, Sawrycki P. Objectivisation of the analgetic effect. Acta Medica 2009; 1-2: 29-33.
41Roszkowski K, Gackowski D, Rozalski R, Dziaman T, Siomek A, Guz J, Szpila A, Foksinski M and Olinski R. Small field radiotherapy of head and neck cancer patients is responsible for oxidatively damaged DNA/oxidative stress on the level of a whole organism. Int J Cancer 2008; 123: 1964-7.
42Roszkowski K, Makarewicz R. PSA bounce phenomenon after External Beam Radiation Therapy for prostate Cancer. Contemporary Oncology 2007; 11(3): 125-8.
43Makarewicz R, Roszkowski K, Lebioda A, Reszke J, Ziolkowska E. PSA bounces after brachytherapy HDR and external beam radiation therapy for prostate cancer. Rep Pract Oncol Radiother 2006; 11(5): 217-22.
44Siomek A, Tujakowski J, Gackowski G, Rozalski R, Foksinski M, Dziaman T, Roszkowski K, Olinski R. Severe oxidatively damaged DNA after cisplatin treatment of cancer patients. Int J Cancer 2006; 119, 2228-30.
45Tujakowski J, Roszkowski K, Ramlau R, Zurawski B. Effectiveness and toxicity of Interleukin 2, Interferon a, and 5-Fluorouracil in patients with Metastatic Renal Cell Cancer. Contemporary Oncology 2006; 10(5): 231-5.
46Ziolkowska E, Roszkowski K, Sitarz R. The influence of Radiotherapy on some of coagulation parameters in patients with Non Small Cell Lung Cancer (NSCLC). Contemporary Oncology 2005; 9(9): 393-5.
47Roszkowski K, Foksinski M. The effect of ionising radiation upon the cellular DNA. Contemporary Oncology 2005; 9(7): 284-6.
48Tujakowski J, Roszkowski K, Zurawski B. Effectiveness and toxicity of complex chemoimmunotherapy for treatment of patients with metastatic melanoma. Contemporary Oncology 2005; 9(6): 269-72.
49Roszkowski K. Evaluation of treatment results and toxicity in cases of repeated radiation therapy of spinal metastasis. NEOPLASMA 2005, 6 (52): 494-6.
50Roszkowski K, Windorbska W. Estimate of toxicity of half-body irradiation metastases to bones. Adv Clin Exp Med 2005; 14(5): 981-4.
51Roszkowski K, Ziolkowska E. Fibrinolysis in neoplastic process. Contemporary Oncology 2005; 5 (62): 196-8.
52Roszkowski K, Windorbska W. Re-irradiation of head and neck cancers. Contemporary Oncology 2004; 5: 259-61
53Roszkowski K. Repair mechanisms of oxidative DNA damage. Contemporary Oncology 2002; 6: 360-5.
54Roszkowski K. Biomarkers of oxidative DNA damage repair in urine. Contemporary Oncology 2002; 5: 272-6.
55Roszkowski K. The role of reactive oxygen species in carcinogenesis proces. Valetudinaria 2002; 4: 41-5.
56Rozalski R, Gackowski D, Roszkowski K, Foksinski M, Olinski R. The level of 8-oxoguanine – possible repair product of oxidative DNA damage – is higher in urine of cancer patients that in control subjects. Cancer Epidemiol Biomarkers Prev 2002; 11(10): 1072-5.
57Olinski R, Gackowski D, Foksinski M, Rozalski R, Roszkowski K, Jaruga P. Oxidative DNA damage: assessment of the role in carcinogenesis, atherosclerosis and acquired immunodeficiency syndrome. Free Rad Biol Med 2002; 33: 192-200.
58Foksinski M, Piekutowski K, Roszkowski K, Olinski R. The role of oestrogenes in carcinogenesis. Contemporary Oncology 2002; 3:137-40
59Gackowski D, Rozalski R, Roszkowski K, Jawien A, Foksinski M, Olinski R. Oxoguanine and 8-oxo-2′-deoxyguanosine levels in human urine do not depend on diet. Free Radic Res 2001; 35: 825-32.
60Roszkowski K, Piekutowski K. Free radicals. Defence activity of antioxidant vitamins in prevention and treatment of cancers. Contemporary Oncology 1999; 4: 143-4.
61Windorbska W, Roszkowski K. Results of postoperative radiotherapy of pituitary adenomas. Contemporary Oncology 1999; 4: 171-3.
62Makarewicz R, Roszkowski K. Zastosowanie nowych radioizotopów w leczeniu nowotworów. Adv Clin Exp Med. 1998; 7: 337-342.